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Mesenchymal stem cells (MSC) are emerging as an effective therapeutic tool in treating
canine osteoarthritis (OA). In this report, we focused on the questions of whether MSC
transplantation has long-term beneficial effects for the improvement in motion and also
evaluated the safety of MSC injection. Visceral adipose tissue, a surgical waste obtained
during routine ovariectomy served as a source of allogeneic MSCs and used to treat
OA. Altogether, fifty-eight dogs were transplanted in the study suffering from OA in
the elbow (42 animals), hip (5), knee (8), ankle (2), and hock (1). The effect of MSC
transplantation was evaluated by the degree of lameness at a 4-5-years follow-up period
based on the owners’ subjective observations. The results showed that 83% of the OA
patients improved or retained improvement in lameness. Clinical safety of the treatment
was assessed by evaluating the coincidence of tumors or other diseases and other
adverse reactions (such as local inflammation) after MSC cell therapy. Two incidences
of local inflammation for <1 week at the site of injection were reported. No other adverse
reactions were detected post-treatment. Sixteen dogs died during the study, 4 due to
cancer and 12 due to other diseases, diagnosed by veterinarians. Overall, our survey
suggests that MSC transplantation has long-term beneficial effects in reducing lameness.
Moreover, no enrichment in a specific cause of death was observed in the transplanted
animals, compared to reported literature. Our data suggest that MSC treatment could
be an effective and safe long-term therapy for canine OA.
Keywords: dogs, osteoarthritis, mesenchymal stem cell, therapy, safety of therapy, long-term follow-up
INTRODUCTION
Osteoarthritis (OA), in which the integrity of joint cartilage is disrupted, is one of the most
prevalent degenerative diseases, both in dogs and humans (1, 2). Due to the low self-regeneration
capacity of the cartilage matrix, the disease is irreversible, thus, the quality of life of the affected
animal is expected to decrease gradually (3). In the United Kingdom alone, 200,000 new cases of
OA are diagnosed in dogs annually, with both external (injury, obesity, age) and genetic factors
Kriston-Pál et al. MSC Therapy of Canine Osteoarthritis
contributing (1, 4, 5). At present, the disease is treated
symptomatically by regularly administering non-steroidal
anti-inflammatory drugs or by repeated injections of hyaluronic
acid (6, 7). Surgical solutions such as arthrodesis or excision
arthroplasty (e.g., total joint replacement) are also used in
more severe cases (8). However, these are invasive procedures,
which may also carry risks of complications such as infections,
instability, or periprosthetic fracture (2). In view of the above,
the development of a safe and long-term regenerative treatment
for OA is highly sought after.
MSCs are excellent candidates for this purpose with a rapidly
expanding published literature demonstrating the effectiveness
of these cells in tissue regeneration in various diseases (9).
An increasing body of evidence now demonstrates that MSCs
administered directly into the joint cavity can reduce the
chronic pain caused by cartilage degeneration, can induce hyaline
cartilage formation, and the treated dogs can live a highly
improved quality of life (10, 11). Though MSCs are present in
all tissues, adipose tissue is a major source of therapeutic MSCs
due to easy access and their high numbers (12).
Besides being able to differentiate into chondrocytes,
MSCs produce bioactive molecules, some of which have
chondroprotective activity, while others are immunosuppressive
and/or anti-inflammatory, thus enabling the safe injection of
MSCs into recipients (13). However, the immunological status
of the microenvironment is also critical since differentiation of
MSCs is inhibited by inflammation (14).
We previously reported that intra-articular injection of
allogeneic, adipose-derived MSCs, combined with hyaluronic
acid induced a significant improvement in clinical signs of
lameness, lasting for 1 year in dogs suffering from elbow OA
(11) and now provide data on the long-term (>4 years) health
status of the treated animals. To the best of our knowledge,
the current report is the first such long-term survey published.
We hypothesized that MSCs are effective in reducing lameness
and improving the quality of life of animals and that local MSC
transplantation is not associated with an increased prevalence of
other diseases or malignancies.
METHODS
Preparation of Visceral Adipose Tissue (AT)
Mesenchymal Stem Cells (MSCs) for
Therapy
MSCs were extracted from visceral adipose tissue. Adipose tissue
was obtained as surgical waste during routine ovariectomy of
healthy, female, mixed-breed dogs (age: between 7 months and 3
years). Donor dogs underwent all routine vaccinations and were
regularly surveyed by veterinarians. Stromal vascular fraction
(SVF) and then AT-MSC cultures were generated as previously
described (11). The purity and differentiation ability of the
resulting MSCs were characterized as described previously (11).
Preparation of AT-MSCs for Therapy
Passage 2 AT-MSCs from two different adipose tissue donors
were thawed, cultured for 3 days, mixed, and suspended in 0.5%
sodium hyaluronate (TRB Chemedica International S.A. Geneva,
Switzerland). Adipose tissue-derivedMSCs (12× 106 ± 3.2×106
cells/injection) were transported to the veterinarian clinics in
syringes at 4–10◦C and injected intra-articularly, within 24 h of
dispensing, in a final volume of 1 mL.
Patient Selection and Assessment of the
Therapy
This study was approved by the National Scientific Ethical
Committee of the National Food Chain Safety Office. All the
dog owners signed an informed consent authorizing treatment
and were informed of the possible risks of joint injections and
potential complications of the procedure.
Fifty-eight dogs suffering from medium or severe
osteoarthritis of various joints were included in the study.
Severity of OA was evaluated by the participating veterinarians
according to a modified method of Black et al. (15) as medium
(intermittent but frequent lameness treated with NSAID
medication or hyaluronic acid injection) or severe (no cartilage
based on the X-ray analysis, continuous pain and lameness,
reduction of joint movement, and presence of joint stiffness).
The inclusion criteria were recurrent lameness and pain
attributed to OA after conventional treatment of dogs (non-
steroidal anti-inflammatory drugs, intra-articular injection of
hyaluronic acid, arthroscopy, or traditional surgery focusing on
debridement and removal of debris from the synovial cavity).
Only those dogs were classed as “improved” that did not require
further conventional treatment due to their OA during the
study period.
The health status, including degree of lameness of the
treated dogs was evaluated by the owners using a questionnaire
modified from Black et al. (15) (Supplementary Table 1), with
an occasional participation of the local veterinarian during the
first year of follow-up. Further follow-up of up-to 5 years was
based on the owners’ subjective observations, reporting the
degree and frequency of lameness and the possible necessity
of pain relief medication since the MSC treatment in personal
telephone interviews. The development of other diseases or
cause of death was diagnosed by veterinarians during the
5 year follow-up period. The owner-assessed efficacy of the
MSC transplantation in OA was evaluated to provide long-
term, supportive information on the clinical outcomes following
this treatment.
There were no exclusion criteria except for pre-existing,
diagnosed cancer.
RESULTS
Overall, fifty-five out of 58 transplanted animals were available
for the long-term follow-up. Forty-two animals suffered from
elbow OA (Table 1 and Supplementary Table 2); all suffering
from elbow dysplasia, except two dogs (aged 12 and 13
years) which had developed cartilage degeneration probably
due to their age. Eleven dogs received MSCs into both
elbows, while 31 animals obtained transplant into one joint
(Supplementary Table 2). Thirty-nine dogs were available for the
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long-term follow-up, by the end of which the average age of the
dogs in the study increased from 3 to 7.3 years.
Sixteen dogs that received theMSC treatment into other joints
[knee (8), hip (5), ankle (2), and hock (1)] (one joint in one
animal, see Supplementary Table 2) were also evaluated in the
long-term follow-up (Table 1). The average age was 4.8 years at
the time of transplantation, increasing to 9 years by the end of
the study period.
Thirty-seven dogs out of 44 (84%), were reported by the
owners to have reduced lameness and an improved quality of life
until the end of the follow-up period or the death of the treated
animals. Several dogs improved, and although suffered from
other joint problems did not require medication. Seven dogs
diagnosed with other joint or spinal problems besides elbow OA
and hence receiving continuous medication were also included
into the survey period of elbow OA (Table 1).
Two of 58 dogs showed a short-term local inflammation
after MSC transplantation. This inflammatory reaction resolved
within a week and did not affect the long-term improvement in
the quality of the dogs’ life (data not shown).
Sixteen dogs between the ages of 7 and 13 died during the
follow-up period, four of them of cancer (between the ages of
11 and 13) and 12 due to various other diseases (aged 7–12
years) (Table 1). Cases of cancer included: melanoma, epithelial
cancer, metastatic cancer, spleen-liver cancer (a single case for
each tumor-type). Other co-morbidities reported by the owners
included: epilepsy, pancreatitis, volvulus, heart failure, ulcers,
neurological, and musculo-skeletal problems. None of these
syndromes were reported more than twice, suggesting that they
may not be associated with the MSC treatment.
DISCUSSION
The aim of this study was to explore whether local intra-articular
transplantation of MSC had long-term beneficial effects on
lameness and hence improving quality of life of the transplanted
animals and whether it caused any serious adverse effects or
correlated with an increased prevalence of other diseases.
Our data presented in this paper suggest that MSC
transplantation results in improvement of motion. In the current
study, 60% of the treated animals belonged to 3 breeds: Golden
Retriever (9), Labrador Retriever (16), and German Shepherd (8).
This is consistent with these breeds being generally recognized as
at high risk of OA (1). The sex of the animals did not correlate
with either the coincidence of OA or the death occurring
subsequently to MSC injection. Our results presented here are
in line with the literature suggesting a beneficial effect of MSC
transplantation in OA (11, 16).
In the cohorts included in the long-term survey, most dogs
suffered from elbow OA (42 dogs out of 58) of which 40
were diagnosed with elbow dysplasia, hence elbow dysplasia
was accepted as the main cause of osteoarthritis in the elbow.
Eighty four percentage of the animals maintained an improved
condition (no lameness/no medication or sporadic lameness
and/or medication during wet weather or with extreme activity)
by the subjective assessment of the owners.
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Osteoarthritis cases in joints other than the elbow (knee, hip,
ankle, and hock) were also evaluated. Eighty four percentage of
the evaluated dogs retained their improved condition after the 4-
5-year follow-up. It should be noted that the dogs in this mixed
group were of higher age than those in the elbow group, and
many patients suffered from joint or spinal problems in addition
to the treated joint.
MSC transplantation does not appear to be associated with
an increase in malignancies or other diseases, and no other
adverse effects emerged due to MSC injection. These findings
are underpinned by: (1) the published literature that supports
that MSC is not a tumorigenic cell type (17, 18); (2) published
findings that local injection into the joint results in the adherence
of MSCs to the damaged cartilage (19) with no reported evidence
for their migration outside of the treated joint. Sixteen dogs out
of 58 transplanted animals died during the long-term follow-up:
four due to cancer in old age (11–13 years) and 12 from other
different causes.
This rate, in spite of the small number of cases overall, is
comparable to large-scale disease prevalence statistics in the USA
(5.3%) thus does not indicate an association between prevalence
of cancer and MSC transplantation (20). Other studies report a
prevalence of 3.4–8.63% for melanoma (in dogs the age average
was 7, 5 years) in Switzerland and Brazil and 3.4% for internal
organ tumors in India over a period of 10 years (21–23).
Published literature demonstrates a 4.9% prevalence of death due
to heart failure in dogs with a median of 9.9 years in the UK
(24), whilst our study reports 3.6%. Of note, the dog population
included in our follow-up study is comprised of older dogs, thus,
the number of deaths due to tumors is expected to be higher than
that in the whole population. In our study, however, the average
age of the dogs that died due to tumors was 12.2 years, while in a
previous report from the USA involving golden retrievers it was
9.83 years (25).
The potential use of allogeneic MSCs for the treatment of
various diseases has also been piloted, including humans and
horses, for instance, for indications such as cardiac damage
post-myocardial infarction andwound healing (26, 27). However,
whilst long-term safety data is still very sparse, evidence is now
emerging on a convincing safety profile for the use of allogeneic
MSCs in cardiac regeneration (28) and autoimmune disease in
man (29) as well as in osteoarthritis in horses (30). Our current
report is in alignment with this broader literature and further
highlights the potential for the use of allogeneicMSCs in a variety
of diseases.
In summary, our data suggest that intra-articular injection
of allogeneic MSCs may provide a long-term improvement in
lameness secondary to OA, based on subjective reporting of the
owners, without the risk of long-term adverse effects on health.
Thus, we conclude that MSC treatment could be an effective and
safe long-term therapy for canine OA.
Though the results overall suggest that MSC treatment is
beneficial for dogs suffering from osteoarthritis, evaluation is
limited by the fact that the improvement was subjectively
compared to the initial state by owners. To overcome these
limitations, a follow-up with rigorous orthopedic examination
performed by veterinarians will be recommended.
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